Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

KVA12123 was well tolerated with no dose limiting toxicities (DLT) and a favorable safety profile at all dose levels in both arms of the study. The poster presentation (SITC #625): “A phase 1/2 ...

The primary objective of this Phase 1 randomized, double-blind, placebo-controlled, multi-part single and multiple ascending dose clinical study is to evaluate the safety, tolerability and ...

Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of evaluable patients achieved stable diseaseColon ...

Oncoinvent announces positive interim results from phase 1/2a studies of Radspherin for treatment of peritoneal carcinomatosis: Oslo, Norway Tuesday, November 12, 2024, 18:00 Hrs ...

In this instalment of our renewed clinical trials round-ups, we look at life sciences research and development announced during the week of 20th to 24th May, from early-stage onwards. During this ...